Thus secondary hyperparathyroidism does play a role in the cardiovascular risk in end stage renal disease (ESRD).[1, 2] However, previous studies evaluating the role of PTH in LVH in ESRD were conflicting.[2, 5–7] The genesis of hypertension in hemodialysis patients is multi-factorial. This evidence concerns the gene PTH and secondary hyperparathyroidism.